| | | | |

Short Term Mesothelioma Survival Better with Conservative Surgery

Researchers at the Icahn School of Medicine at Mount Sinai have added their voices to the ongoing debate over the best type of surgery for malignant pleural mesothelioma.

After a meta-analysis of 30-day mortality among 500 mesothelioma patients, the group has come down on the side of pleurectomy decortication (PD), the more conservative — and less risky — of the two major types of mesothelioma surgery.

Mesothelioma Surgery: EPP vs. P/D

Pleural mesothelioma, also referred to as asbestos cancer, is notoriously difficult to treat. Successful mesothelioma treatment usually involves a combination of therapies, such as Alimta (pemetrexed), radiotherapy, and curative surgery in patients who are healthy enough to undergo it. (Surgery is currently only recommended for patients with epithelioid mesothelioma, although recent research has challenged that idea.) Fewer than 1 in 5 pleural mesothelioma patients qualify for surgery.

There are two primary types of mesothelioma surgery — exrapleural pneumonectomy (EPP) and pleurectomy decortication (PD).

Surgeons worldwide continue to disagree on which type of surgery is preferrable. The late David Sugarbaker, MD, developed the EPP procedure, which involves removal of the diseased pleural lining, the closest lung, the diaphragm, the pericardium, and a number of other at-risk tissues.

Dr. Sugarbaker and his colleagues at Baylor St. Luke’s Medical Center in Houston boasted some of the best mesothelioma survival rates in the world using EPP.

However, a growing number of surgeons, including the Icahn School of Medicine group, have begun to favor the less traumatic pleurectomy decortication procedure developed by Dr. Robert Cameron at UCLA, which includes removal of the pleura and other tissues, but leaves the lungs in place.

Surgeons who favor this approach say it allows for a better quality of life for mesothelioma patients.

30-Day Mesothelioma Survival After Surgery

The newest study on the two types of mesothelioma surgery, published in the Journal of Surgical Oncology, focuses on survival odds during the critical period in the month following surgery.

They analyzed data from the New York Statewide Planning and Research Cooperative System (SPARCS) on 500 pleural mesothelioma patients who underwent either EPP or PD.

Although no difference was found in the number of complications that developed right after surgery or the number mesothelioma patients who died while still in the hospital, differences between the EPP and PD patients began to show up quickly after patients went home.

Nearly half (46%) of the EPP patients developed surgery-related complications, versus just 24% of the PD patients. One of the most significant and common complications were heart rhythm problems called arrythmias, which occurred five times as often in the EPP group (20% vs. 5%).

“Postoperative mortality, postoperative complications, and particularly supraventricular arrhythmia are less frequent after PD vs. EPP,” writes author Emanuela Taioli, MD, PhD. “PD, a less invasive surgery, may provide a better option when technically feasible for patients with malignant pleural mesothelioma.”

Source:

Van Gerwen, M, et al, “Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma”, Journal of Surgical Oncology, October 7, 2018, Epub ahead of print

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…